The Breast Cancer Therapeutics Market is set to exceed USD 28 billion by 2024; according to a new research report by Global Market Insights, Inc. Rising prevalence of breast cancer, launch of numerous diagnostic and screening programs globally and favorable insurance and reimbursement policies will serve as high influential factors for the breast cancer therapeutics market growth.
Advancement in technologies for cancer biology, increasing research and development for introduction of novel drugs to treat the disease will stimulate industry growth over the coming years. Rising adoption of minimally invasive cancer therapy methods should improve patient compliance. Moreover, increasing awareness towards disease prevention, early screening and diagnosis will further propel the industry size. However, prohibitive cost associated with breast cancer therapeutics may restrain its adoption in emerging economies. Compliance to therapy may reduce due to high maintenance treatment price.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/466
Targeted drug therapy market accounted for largest market share in 2016 and is forecast to witness substantial growth over the coming years owing to associated factors like targeting certain parts of tumor cells that allow the tumor cells to grow faster and abnormally, resulting in turn off or blockage of chemical signals. Furthermore, features such as stopping growth of new blood vessels, changing proteins, triggering immune system, and carrying toxins to the tumor cells to kill cells will drive the therapy demand over forecast years.
Chemotherapy drug segment is set to witness a low growth rate, due to factors like attacking all cells that are growing quickly and inflated cost associated with the drugs resulting in financial burden. Moreover, undesirable chemotherapy reactions and establishment of resistance to drugs resulting in multi-drug resistance are the major restraining factor in chemotherapy usage. Retail pharmacies held the largest market share in 2016 and will continue to be the biggest distribution channel for the industry over the forecast period. Growing shift from specialty to retail pharmacies owing to reimbursement variations and prolonged usage of oral formulations, particularly for targeted drug therapies will drive the business growth.
Moreover, growing number of retail store and augmented investment in retail stores by retail giants in developing as well as developed economies will further boost the industry share. Hospitals segment will grow at a considerable rate in the coming year pertaining to administration of drugs available in injectable forms in hospital settings which are reimbursed by patient’s medical benefits.
U.S. breast cancer therapeutics market accounted for the highest regional share in 2016 due to growing prevalence of breast cancer and increasing R&D funding through public and private sectors. Growing elderly population, breast feeding discontinuation at an early stage and increased access to cancer care will stimulate industry growth. Moreover, rising demand for tumor therapeutics will strongly drive industry growth in the country.
Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/466
Some of the major players in global breast cancer therapeutics market are AstraZeneca, Roche Diagnostics, Pfizer, Novartis, Eisai, Eli Lilly, Sanofi, and Celgene. Roche holds the largest market share owing to wide geographical presence and strong product portfolio. It is expected to dominate the industry revenue over the coming years. The company should face intense competition from other players such as AstraZeneca and Pfizer over the forecast years.